In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test

Abstract

Abstract: Objective To investigate the in vitro acvtivity of posaconazole against 43 clinical isolates of zygomycetous fungi.Methods Forty-three clinical strains were re-identified by ITS region sequencing. The minimal inhibitory concentration of posaconazole against 43 clinical isolates of zygomycetous fungi was assayed by E-test.Results Forty-three strains included Rhizopus microsporus (12 isolates),Mucor irregularis (12 isolates),R.oryzae (10 isolates),Lichtheimia ramosa (3 isolates),L.ornata (1 isolate),Syncephalastrum racemosum (1 isolate),Rhizomucor pusillus (1 isolate),M.circinelloides (1 isolate),M.indicus (1 isolate) and M.hiemalis ( 1 isolate). The MIC ranges of posconazole against Mucor spp.,Rhizopus spp. and Lichtheimia spp. in E-test were 0.19->32 μg/mL, 0.19-3 μg/mL and 0.002-0.38 μg/mL, respectively. The MIC values of posaconazole against Syncephalastrum racemosum and Rhizomucor pusillus were 1 μg/mL and 0.19 μg/mL, respectively.Conclusion Most isolates of zygomycetous fungi were susceptible to posaconazole. The MIC values of Mucor spp. were relatively variable.

Key words: posaconazole, E-test, Zygomycetous fungi

CLC Number:

R 379.9

WANG Si-bu, WAN Zhe, LI Ruo-yu, YU Jin. In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test[J]. Chinese Journal of Mycology, 2012, 7(3): 142-145.

References

[1] Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653.
[2] Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease[J]. Clin Microb Rev, 2000, 13(2): 236-301.
[3] Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal[J]. Lancet Infect Dis, 2005, 5(12): 775-785.
[4] Rodríguez, MM, Serena C, Mariné M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae[J]. Antimicrob Agents Chemother, 2008, 52(10): 3786-3788.
[5] Sun QN, Najvar LK, Bocaneqra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model[J]. Antimicrob Agents Chemother, 2002, 46(7): 2310-2312.
[6] Kontoyiannis DP, Lewis RE. How I treat mucormycosis[J]. Blood, 2011, 118(5):1216-1224.
[7] 王思卜,张杰,余进等. 用ITS和TUB序列差异鉴定临床相关波氏假阿利什霉/尖端赛多孢[J]. 中华检验医学杂志,2012,12(34): 1084-1087.
[8] Barry AL, Pfaller MA, Brown SD, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents[J]. J Clin Microbiol, 2000, 38(9):3457-3459.
[9] lvarez E, Cano J, Stchiqel AM, et al. Two new species of Mucor from clinical samples[J]. Med Mycol, 2011, 49(1):62-72.
[10] Schell WA, O'Donnell K,Alspaugh JA. Heterothallic mating in Mucor irregularis and first isolate of the species outside of Asia[J]. Med Mycol, 2011, 49(7): 714-723.
[11] Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, et al. Species recognition and clinical relevance of the Zygomycetous genus Lichtheimia (syn. Absidia Pro Parte, Mycocladus)[J].J Clin Microbiol, 2010, 48(6) : 2154-2170.
[12] Almyroudis NG, Sutton DA, Fothergill AW, et al.In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents[J]. Antimicrob Agents Chemother,2007, 51(7): 2587-2590.
[13] Sun QN, Fothergill AW, McCarthy DI, et al.In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes[J]. Antimicrob Agents Chemother, 2002, 46(5): 1581-1582.
[14] Torres-Narbona M,Guinea J,Martinez-Alarcon J,et al.In vitro activities of amphotericin B,caspofungin,itraconazole,posaconazole,and voriconazole against 45 clinical isolates of zygomycetes:comparison of CLSI M38-A,Sensititre YeastOne,and the Etest[J].Antimicrob Agents Chemother,2007,51(3):1126-1129.